{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:34:49Z","timestamp":1793230489749,"version":"4.5.0"},"reference-count":43,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Current Research Funds 2023, Ministry of Health, Italy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Migraine is one of the most disabling disorders in the world, associated with poor quality of life. Migraine prevention strategies have increasingly evolved since monoclonal antibodies against the calcitonin gene-related peptide (CGRP), or its receptor, were identified. CGRP is the ideal target of monoclonal antibodies (mAbs). In particular, erenumab is the mAb that has shown good therapeutic efficacy in reducing pain intensity and having high tolerability. In this study, we aimed to investigate the efficacy of erenumab on both cognitive performance and psychological well-being. This was a pilot study with a retrospective design that included 14 subjects (2 males and 12 females), with a mean age of 52.29 \u00b1 9.62, who attended the Headache and Migraine outpatient clinic of the IRCCS Centro Neurolesi Bonino-Pulejo of Messina. The evaluation consisted of measuring cognitive and psychological functioning. Comparing clinical and psychometric test scores between baseline and follow-up, we found a significant improvement in both cognitive performance and quality of life. We also observed a decrease in migraine disability. Our findings have shown improvements in global cognitive performance and quality of life in migraine patients taking erenumab.<\/jats:p>","DOI":"10.3390\/medicina59050936","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:49:51Z","timestamp":1683888591000},"page":"936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Migraine Treatment Using Erenumab: Can Lead to a Cognitive and Psychological Qualitative Improvement?"],"prefix":"10.3390","volume":"59","author":[{"given":"Michele","family":"Torrisi","sequence":"first","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-3832","authenticated-orcid":false,"given":"Francesco","family":"Corallo","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-6098","authenticated-orcid":false,"given":"Viviana","family":"Lo Buono","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Di Cara","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Grugno","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lo Presti","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Quartarone","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7509-3833","authenticated-orcid":false,"given":"Maria Cristina","family":"De Cola","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d S.S. 113 Via Palermo, C\/da Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/14728222.2020.1724285","article-title":"Calcitonin gene-related peptide (CGRP): Role in migraine pathophysiology and therapeutic targeting","volume":"24","author":"Wattiez","year":"2020","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_2","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211\u20131259."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","article-title":"Chronic migraine pathophysiology and treatment: A review of current perspectives","volume":"2","author":"Mungoven","year":"2021","journal-title":"Front. Pain Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s40064-016-2211-8","article-title":"Recent advances in migraine therapy","volume":"5","author":"Antonaci","year":"2016","journal-title":"Springerplus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/0333102415587704","article-title":"International Classification of Headache Disorders 3rd edition beta-based field testing of vestibular migraine in China: Demographic, clinical characteristics, audiometric findings and diagnosis statues","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Houtveen, J.H., and Sorbi, M.J. (2013). Prodromal functioning of migraine patients relative to their interictal state-an ecological momentary assessment study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0072827"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0333102410381145","article-title":"Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)","volume":"31","author":"Blumenfeld","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","article-title":"Disability, quality of life, productivity impairment and employer costs of migraine in the workplace","volume":"22","author":"Shimizu","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: A narrative review","volume":"30","author":"Agostoni","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the quality standards Subcommittee of the American Academy of neurology and the American headache society","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","article-title":"Pathophysiology, prevention, and treatment of medication overuse headache","volume":"18","author":"Diener","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/bs.pbr.2020.06.019","article-title":"Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants","volume":"255","author":"Chiang","year":"2020","journal-title":"Prog. Brain Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s42466-020-00057-1","article-title":"Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor","volume":"2","author":"Diener","year":"2020","journal-title":"Neurol. Res. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","article-title":"European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)","volume":"21","author":"Sacco","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1756286420927119","DOI":"10.1177\/1756286420927119","article-title":"The role of erenumab in the treatment of migraine","volume":"13","author":"Andreou","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Deng, H., Li, G.-G., Nie, H., Feng, Y.-Y., Guo, G.-Y., Guo, W.-L., and Tang, Z.-P. (2020). Efficacy and safety of calcitonin- gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine an updated systematic review and meta-analysis. BMC Neurol., 15.","DOI":"10.21203\/rs.2.15211\/v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.18071\/isz.73.0129","article-title":"Evaluation of anxiety, depression and marital relationships in patients with migraine","volume":"73","author":"Demir","year":"2020","journal-title":"Ideggyogy Sz."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1129-2377-15-32","article-title":"The relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine","volume":"15","author":"Eraslan","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jpsychores.2015.09.014","article-title":"Symptom dimensions of affective disorders in migraine patients","volume":"79","author":"Louter","year":"2015","journal-title":"J. Psychosom. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/head.13215","article-title":"Associations Between Depression\/Anxiety and Headache Frequency in Migraineurs: A Cross-Sectional Study","volume":"58","author":"Chu","year":"2018","journal-title":"Headache"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","article-title":"Depression and risk of transformation of episodic to chronic migraine","volume":"13","author":"Ashina","year":"2012","journal-title":"J. Headache Pain"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/head.13911","article-title":"Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR)","volume":"60","author":"Pearl","year":"2020","journal-title":"Headache"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s10194-018-0933-4","article-title":"Cognitive dysfunction and migraine","volume":"19","author":"Vuralli","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-016-0667-0","article-title":"Cognitive dysfunctions and psychological symptoms in migraine without aura: A cross-sectional study","volume":"17","author":"Santangelo","year":"2016","journal-title":"J. Headache Pain"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 33, 629\u2013808.","DOI":"10.1177\/0333102413485658"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1744806917740233","DOI":"10.1177\/1744806917740233","article-title":"Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications","volume":"13","author":"Yeh","year":"2017","journal-title":"Mol. Pain"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0333102411417466","article-title":"Migraine and cognitive decline in the population-based EVA study","volume":"31","author":"Rist","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10194-017-0758-6","article-title":"Duration and frequency of migraines affect cognitive function: Evidence from neuropsychological tests and event-related potentials","volume":"18","author":"Huang","year":"2017","journal-title":"J. Headache Pain"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Russo, M., De Rosa, M.A., Calisi, D., Consoli, S., Evangelista, G., Dono, F., Santilli, M., Granzotto, A., Onofrj, M., and Sensi, S.L. (2022). Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911418"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1177\/03331024211028966","article-title":"Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies","volume":"41","author":"Lipton","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/TCRM.S263825","article-title":"Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes","volume":"18","author":"Sacco","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/jnrp.jnrp_146_18","article-title":"Migraine and mood disorders: Prevalence, clinical correlations and disability","volume":"10","author":"Rammohan","year":"2019","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","article-title":"Migraine and its psychiatric comorbidities","volume":"87","author":"Minen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/head.13914","article-title":"The effect of psychiatric comorbidities on headache-related disability in migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study","volume":"60","author":"Lipton","year":"2020","journal-title":"Headache J. Head Face Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/head.13613","article-title":"Life with Migraine: Effects on Relationships, Career, and Finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study","volume":"59","author":"Buse","year":"2019","journal-title":"Headache"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s10194-015-0584-7","article-title":"Impact of headache disorders in Italy and the public-health and policy implications: A population-based study within the Eurolight Project","volume":"16","author":"Allena","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","article-title":"My Migraine Voice survey: A global study of disease burden among individuals with migraine for whom preventive treatments have failed","volume":"19","author":"Martelletti","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/head.14291","article-title":"A real-world, observational study of erenumab for migraine prevention in Canadian patients","volume":"62","author":"Becker","year":"2022","journal-title":"Headache"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:44Z","timestamp":1760124824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/5\/936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["medicina59050936"],"URL":"https:\/\/doi.org\/10.3390\/medicina59050936","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}